SCHEMBL25825537

SCHEMBL25825537

CC(C)(C)OC(=O)NC1CCN(C2CN(c3ccc(-c4ccc(OCc5ccccc5)nc4OCc4ccccc4)cc3F)C2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 1/20 0.42
SKP1 P63208 1/20 0.42
SKP2 Q13309 1/20 0.42
ALOX5AP P20292 1/20 0.40
FEN1 P39748 1/20 0.40
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
OGFRL1 Q5TC84 1/20 0.39
RORC P51449 3/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
BTK Q06187 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
PRMT5 O14744 2/20 0.37
AKT1 P31749 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
CNR1 P21554 1/20 0.36
KCNA3 P22001 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30965571 1.00 CKS1B (0.42) CKS1BSKP1SKP2ALOX5APFEN1
SCHEMBL25942674 0.96 CKS1B (0.42) CKS1BSKP1SKP2ALOX5APFEN1
SCHEMBL31653790 0.94 CKS1B (0.47) CKS1BSKP1SKP2ALOX5APFEN1
SCHEMBL25819587 0.93 CKS1B (0.43) CKS1BSKP1SKP2ALOX5APFEN1
SCHEMBL25935573 0.90 CKS1B (0.43) CKS1BSKP1SKP2ALOX5APFEN1
SCHEMBL30136037 0.86 FFAR4 (0.38) CKS1BSKP1SKP2ALOX5APFEN1
SCHEMBL25940322 0.86 FFAR4 (0.38) CKS1BSKP1SKP2ALOX5APFEN1
SCHEMBL27225280 0.85 CKS1B (0.39) CKS1BSKP1SKP2ALOX5APFEN1
SCHEMBL30136109 0.83 DPP4 (0.37) KMT2AFFAR4CNR1
SCHEMBL25419978 0.82 FFAR4 (0.43) ALOX5APFEN1FFAR4PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 CKS1B 43/4885SKP1 1092/4885SKP2 42/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 CKS1B 36/4885SKP1 241/4885SKP2 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.